Batiraxcept has "Best in Class Potential" - H.C. Wainwright Reiterates Buy Rating on Aravive (ARAV) with $26 Price Target Jun 6, 2022 06:24AM
Cantor Fitzgerald Reiterates Overweight Rating, $18 Price Target on Aravive (ARAV), "Peak Sales Potential of AVB-500 Remains Underappreciated" May 12, 2022 09:44AM